Smoothened Homolog Pipeline Review, Market Strategies, Key Players, Analysis Report 2019

Posted on 2019-10-01 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, USA, 2019-Oct-01 — /EPR Network/ —

Market Research Hub (MRH) has actively uploaded a smart research report titled “Smoothened Homolog-Pipeline Review, H2 2019”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Smoothened Homolog. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section of the report contains imperative market data that can prove useful for new entrants and industry players to draw crucial tactics.

Request Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519503

Smoothened Homolog – Pipeline Review, H2 2019

Summary

According to the recently published report ‘Smoothened Homolog – Pipeline Review, H2 2019’; Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Smoothened Homolog (Protein Gx or SMO) – Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog’s proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

The report ‘Smoothened Homolog – Pipeline Review, H2 2019’ outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Gastrointestinal, Immunology and Undisclosed which include indications Adenocarcinoma Of The Gastroesophageal Junction, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Medulloblastoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Basal Cell Carcinoma (Basal Cell Epithelioma), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Peritoneal Cancer, Small-Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Chronic Myelomonocytic Leukemia (CMML), Cirrhosis, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Graft Versus Host Disease (GVHD), Leukemia, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC) and Unspecified.

Scope

– The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
– The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
– The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Complete Research Report with TOC@ https://www.marketresearchhub.com/report/smoothened-homolog-pipeline-review-h2-2019-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smoothened Homolog (Protein Gx or SMO) – Overview
Smoothened Homolog (Protein Gx or SMO) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Smoothened Homolog (Protein Gx or SMO) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smoothened Homolog (Protein Gx or SMO) – Companies Involved in Therapeutics Development
AlfaSigma SpA
F. Hoffmann-La Roche Ltd
Genentech Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
IMPACT Therapeutics Inc
Mayne Pharma Group Ltd
PellePharm Inc
Pfizer Inc
Sun Pharma Advanced Research Company Ltd
Smoothened Homolog (Protein Gx or SMO) – Drug Profiles
glasdegib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSA-10 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-1708 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-5471 – Drug Profile
Product Description
Mechanism Of Action

To be continue#@

Make An Enquiry About This Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519503

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceutical market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick